Welcome to our dedicated page for Senseonics news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics stock.
Senseonics Holdings, Inc. (SENS) is a medical technology company in the surgical and medical instrument manufacturing industry, focused on glucose monitoring products for people with diabetes. Company news frequently centers on its long-term implantable continuous glucose monitoring (CGM) systems, Eversense 365 and Eversense E3, which use an under-the-skin sensor, a smart transmitter, and a mobile app to deliver frequent glucose readings.
News updates for SENS often include financial results and revenue updates, such as preliminary unaudited revenue announcements and quarterly earnings reports. These disclosures provide information on revenue trends, new patient growth, and other operating metrics related to the rollout and adoption of Eversense 365 in the United States and other markets.
Investors and observers can also find corporate and capital markets news, including announcements about a 1-for-20 reverse stock split, special stockholder meetings, and the company’s decision to transfer its stock exchange listing from the NYSE American to the Nasdaq Global Select Market. SEC-related press releases, such as those tied to Form 8-K filings, often accompany these events.
Another key category of Senseonics news involves commercialization and partnership developments. The company has reported on its collaboration with Ascensia Diabetes Care and the planned transition of Eversense 365 commercialization and distribution to Senseonics, as well as its work with Sequel MedTech to integrate the Eversense 365 CGM with the twiist automated insulin delivery system. These updates describe how Eversense technology is being deployed and supported in the diabetes care ecosystem.
Visitors to the SENS news page can review these press releases and related updates to follow Senseonics’ progress in long-term implantable CGM technology, its commercialization strategy for Eversense products, and its ongoing financial and corporate reporting. Regularly checking this page can help readers track how the company’s medical device platform and public company activities evolve over time.
Senseonics (NASDAQ: SENS) and Sequel Med Tech announced full U.S. availability of the twiist Automated Insulin Delivery system integrated with the Eversense 365 continuous glucose monitor on Feb 19, 2026. twiist is the first AID compatible with a year‑long CGM, pairing twiist precision with Eversense 365's 365 days of continuous readings to reduce sensor changes and re‑pairing while maintaining high CGM accuracy.
The combination is in real‑world care settings and offers people with type 1 diabetes an alternative to shorter‑duration sensors.
Senseonics (NASDAQ: SENS) received CE Mark approval for the Eversense 365 continuous glucose monitor, clearing commercialization across the EU and enabling planned launches in Germany, Italy, Spain, and Sweden in the coming months. The device is the first one-year implantable CGM, following FDA clearance and U.S. launch in 2024. The company says the approval expands its reachable EU patient population by over 30 million and positions Eversense 365 for integration with automated insulin delivery systems.
Senseonics (NASDAQ: SENS) announced management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 11, 2026 in Snowbird, Utah.
Investors seeking a meeting are advised to contact their BTIG representatives to request a meeting with Senseonics management.
Senseonics (NASDAQ: SENS) reported preliminary unaudited Q4 2025 revenue of ~$14.2M (+71% YoY) and preliminary full‑year 2025 revenue of ~$35.2M (+~57% YoY), the largest quarterly and annual revenue in company history. The company expects to report audited results after market close on March 2, 2026 and held cash of approximately $94.3M as of December 31, 2025. Senseonics introduced 2026 revenue guidance of $58–$62M (≈65%–76% growth) and forecasted ~50% gross margin. Company highlights include 103% U.S. new patient growth in Q4, FDA IDE approval and enrollment for the Gemini pivotal trial, and the commercial transition of Eversense 365 from Ascensia effective January 1, 2026.
Senseonics (NASDAQ: SENS) and Sequel MedTech launched a commercial integration pairing the Eversense 365 one‑year implantable CGM with Sequel’s twiist automated insulin delivery (AID) system, with first commercial patients already treated and broad availability expected by March 2026. The integration combines Eversense 365’s year‑long, implantable glucose sensing and minimal interruptions with twiist’s iiSure technology for direct insulin volume measurement and faster occlusion detection, and the twiist Loop algorithm for automatic insulin adjustments based on real‑time and predicted glucose.
The partnership aims to reduce sensor changes and re‑pairing while offering personalized diabetes management and improved automation for people with type 1 diabetes.
Vistagen (Nasdaq: VTGN) appointed Nick Tressler as Chief Financial Officer effective December 1, 2025. Mr. Tressler has over 20 years of life‑science financial leadership, most recently serving as CFO of DYNEX Technologies and previously at American Gene Technologies and Senseonics (Nasdaq: SENS). He held senior roles at Sucampo (acquired 2018) and MedImmune (acquired 2007) and holds an MBA from Johns Hopkins.
The Compensation Committee granted an inducement incentive option for 150,000 shares with an exercise price equal to the December 1, 2025 closing price; vesting is 25% after one year, then monthly ratable vesting over 36 months.
Senseonics (NYSE American: SENS) will participate in the Stifel 2025 Healthcare Conference in New York on Wednesday, November 12, 2025. The company will take part in a fireside chat and hold one-on-one meetings at 4:40 PM ET. Interested parties may watch a live and recorded webcast via the company’s Investor Relations website at www.senseonics.com. The presentation provides management access for investors and analysts to discuss the company’s long-term implantable CGM systems and strategic outlook.
Senseonics (SENS) will transfer its common stock listing from NYSE American to the Nasdaq Global Select Market, effective after market close on November 14, 2025. The company expects its shares to begin trading on Nasdaq under the existing ticker SENS on November 17, 2025. The move is described as a decision made in the best interest of the company and its stockholders and does not change the company ticker symbol.
Senseonics (NYSE American: SENS) reported third quarter 2025 results with $8.1M revenue, up 90% YoY, driven by a 160% increase in U.S. new patient starts. Q3 gross profit was $3.5M versus a gross loss in Q3 2024. Net loss narrowed to $19.5M ($0.43/share) from $24.0M a year earlier. Management completed a 1-for-20 reverse stock split (approx. 41M shares outstanding) and plans to move listing to Nasdaq Global Market on Nov 17, 2025. Full-year 2025 revenue outlook is ~$35M, with expected 2025 gross margins of 35–40% and ~$60M cash used in operations.
Senseonics (NYSE American: SENS) will release third quarter 2025 financial results after market close on Wednesday, November 5, 2025. Management will host a conference call and concurrent webcast to review Q3 2025 performance starting at 4:30 p.m. Eastern Time the same day.
The webcast link will be posted and archived under Investor Relations > Events & Publications at www.senseonics.com. To join the call, dial 1-800-343-5172 (US/Canada) or 1-203-518-9856 (International) and use passcode SENSQ3, connecting about ten to five minutes before the start time.